CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results

NEXT STORY
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
PREV STORY
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results

ROCKVILLE, Md., May 03, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma

The first patients have been screened and a first patient has been dosed in ...

author_avatar
NASDAQ Market News

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology ...

author_avatar
NASDAQ Market News